Feb 09, 2023 / 06:00PM GMT
Seamus Christopher Fernandez - Guggenheim Securities, LLC, Research Division - Senior Analyst of Global Pharmaceuticals
Okay. Good afternoon, everybody. Thanks for joining us for today's fireside chat discussion with Bristol-Myers Squibb. I'm Seamus Fernandez, Guggenheim's Global Biopharmaceuticals Analyst. We are here at our fifth annual oncology conference. And to my right is Chris Boerner, Chief Commercialization Officer of Bristol-Myers Squibb. I've asked Chris to share a few slides on where Bristol is in its transformation journey. And after that, we're going to jump right into Q&A.
Christopher S. Boerner - Bristol-Myers Squibb Company - Executive VP & Chief Commercialization Officer
Thanks, Seamus. It's great to be here with you, and great to see everybody. We did think it would be helpful to kick off this fireside by just reiterating how we think about the growth profile of the company and it really sort of starts on this slide.
As we look at BMS today, BMS is in a very strong position. We are -- we've spent the last few years really
Bristol-Myers Squibb Co at Guggenheim Healthcare Talks Oncology Day Transcript
Jan 22, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers